Asthma and HIV drug drive revenue growth, GlaxoSmithKline (GSK.US) Q1 profits exceed expectations, maintain full-year performance outlook.

According to the Zhtng Cijng APP, British pharmaceutical giant GlaxoSmithKline (GSK.US) released its first quarter performance report on Friday. The financial data showed that the company's first quarter profits exceeded expectations, especially with the strong sales of asthma and HIV treatment drugs exceeding expectations, offsetting the negative impact of the overall sales performance of the vaccine business not meeting expectations.